CA2789654A1 - Crystalline forms of the tri-mesylate salt of perphenazine-gaba and process of producing the same - Google Patents

Crystalline forms of the tri-mesylate salt of perphenazine-gaba and process of producing the same Download PDF

Info

Publication number
CA2789654A1
CA2789654A1 CA2789654A CA2789654A CA2789654A1 CA 2789654 A1 CA2789654 A1 CA 2789654A1 CA 2789654 A CA2789654 A CA 2789654A CA 2789654 A CA2789654 A CA 2789654A CA 2789654 A1 CA2789654 A1 CA 2789654A1
Authority
CA
Canada
Prior art keywords
perphenazine
crystalline form
aminobutyrate
trimesylate
aminobutyrate trimesylate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2789654A
Other languages
English (en)
French (fr)
Inventor
Abraham Nudelman
Ada Rephaeli
Irit Gil-Ad
Abraham Weizman
Mazal Shaul
Efrat Halbfinger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ramot at Tel Aviv University Ltd
Bar Ilan University
BiolineRx Ltd
Original Assignee
Ramot at Tel Aviv University Ltd
Bar Ilan University
BiolineRx Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramot at Tel Aviv University Ltd, Bar Ilan University, BiolineRx Ltd filed Critical Ramot at Tel Aviv University Ltd
Publication of CA2789654A1 publication Critical patent/CA2789654A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/18—[b, e]-condensed with two six-membered rings
    • C07D279/22—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom
    • C07D279/24—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom with hydrocarbon radicals, substituted by amino radicals, attached to the ring nitrogen atom
    • C07D279/28—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom with hydrocarbon radicals, substituted by amino radicals, attached to the ring nitrogen atom with other substituents attached to the ring system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA2789654A 2010-02-24 2011-02-24 Crystalline forms of the tri-mesylate salt of perphenazine-gaba and process of producing the same Abandoned CA2789654A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US30748110P 2010-02-24 2010-02-24
US30748210P 2010-02-24 2010-02-24
US61/307,481 2010-02-24
US61/307,482 2010-02-24
PCT/IB2011/000915 WO2011104637A2 (en) 2010-02-24 2011-02-24 Crystalline forms of the tri-mesylate salt of perphenazine-gaba and process of producing the same

Publications (1)

Publication Number Publication Date
CA2789654A1 true CA2789654A1 (en) 2011-09-01

Family

ID=44507308

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2789654A Abandoned CA2789654A1 (en) 2010-02-24 2011-02-24 Crystalline forms of the tri-mesylate salt of perphenazine-gaba and process of producing the same

Country Status (9)

Country Link
US (2) US8377929B2 (enExample)
EP (1) EP2539857A4 (enExample)
JP (1) JP2013520488A (enExample)
CN (1) CN102858345A (enExample)
AU (1) AU2011219529A1 (enExample)
CA (1) CA2789654A1 (enExample)
IL (1) IL221461A0 (enExample)
MX (1) MX2012009821A (enExample)
WO (1) WO2011104637A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7544681B2 (en) * 2001-09-27 2009-06-09 Ramot At Tel Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
ES2400772T3 (es) * 2005-06-07 2013-04-12 Ramot At Tel Aviv University Ltd. Sales novedosas de fármacos psicotrópicos conjugados y procedimientos para la preparación de las mismas
JP5192485B2 (ja) * 2006-07-17 2013-05-08 ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド 向精神性薬物またはｇａｂａアゴニストと有機酸とを含むコンジュゲート、ならびに疼痛および他のｃｎｓ障害を治療するためのそれらの使用
WO2009101616A1 (en) * 2008-02-11 2009-08-20 Ramot At Tel Aviv University Ltd. Novel conjugates for treating neurodegenerative diseases and disorders
US8975251B2 (en) 2009-12-09 2015-03-10 Bar-Ilan University Methods of improving cognitive functions
AU2011219529A1 (en) 2010-02-24 2012-08-30 Bar-Ilan University Crystalline forms of the tri-mesylate salt of perphenazine-GABA and process of producing the same
WO2012038963A1 (en) 2010-09-22 2012-03-29 Ramot At Tel-Aviv University Ltd. An acid addition salt of a nortriptyline-gaba conjugate and a process of preparing same
US10562930B1 (en) * 2018-08-31 2020-02-18 Praxis Precision Medicines, Inc. Salts and crystal forms of GABAA positive allosteric modulator

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1460713A (en) 1973-06-08 1977-01-06 Kefalas As 7-fluoro substituted phenothiazines method for preparation thereof and compositions bladed rotor for a gas turbine engine
US5525727A (en) 1982-05-18 1996-06-11 University Of Florida Brain-specific drug delivery
GB8608335D0 (en) 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5780590A (en) 1993-10-15 1998-07-14 Rhone-Poulenc Rorer Pharmaceuticals Inc. Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides
US5534522A (en) 1995-06-07 1996-07-09 Warner-Lambert Company (R)-(Z)-1-azabicyclo [2.2.1] heptan-3-one,O-[3-(3-methoxyphenyl)-2-propynyl] oxime maleate as a pharmaceutical agent
US5952365A (en) 1995-07-13 1999-09-14 Anormed Inc. 2- 2-(Dimethylamino)ethyl!-8,8-dipropyl-2-azaspiro 4.5!decane dimaleate
DE19622489A1 (de) 1996-06-05 1997-12-11 Hoechst Ag Salze des 3-(2-(4-(4-(Amino-imino-methyl)-phenyl)-4- methyl-2,5-dioxo-imidazolidin-1-yl)-acetylamino)-3- phenyl-propionsäure-ethylesters
US6130221A (en) 1997-03-05 2000-10-10 Nymox Corporation Pharmaceutical agents that impede the initiation and progression of primary and secondary DMS disruptions
YU37602A (sh) 1999-12-01 2005-07-19 Ucb S.A. Derivat pirolidinacetamida sam ili u kombinaciji za tretman poremećaja cns
JP2005097120A (ja) 2000-10-06 2005-04-14 Mochida Pharmaceut Co Ltd ４−ヒドロキシピペリジン誘導体の非潮解性塩
US7544681B2 (en) * 2001-09-27 2009-06-09 Ramot At Tel Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
CA2461663A1 (en) 2001-09-27 2003-04-03 Ramot At Tel Aviv University Ltd. Conjugated anti-psychotic drugs and uses thereof
US7005138B2 (en) 2001-12-21 2006-02-28 Duramed Pharmaceuticals, Inc. Method of systematically delivering SSRIs
US20040092504A1 (en) 2002-11-12 2004-05-13 Anuthep Benja-Athon Definitive medications for treating fibromyalgia
TW200616604A (en) 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
ES2400772T3 (es) * 2005-06-07 2013-04-12 Ramot At Tel Aviv University Ltd. Sales novedosas de fármacos psicotrópicos conjugados y procedimientos para la preparación de las mismas
CN101247837B (zh) * 2005-06-07 2013-03-20 特拉维夫大学拉莫特有限公司 新的轭合精神活性药物的盐及其制备方法
TWI378091B (en) * 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
WO2009094563A2 (en) 2008-01-25 2009-07-30 Xenoport, Inc. Crystalline form of calcium-salts of (3s)-aminomethyl-b-methyl-hexanoic acids and methods of use
AU2011219529A1 (en) 2010-02-24 2012-08-30 Bar-Ilan University Crystalline forms of the tri-mesylate salt of perphenazine-GABA and process of producing the same
WO2012038963A1 (en) 2010-09-22 2012-03-29 Ramot At Tel-Aviv University Ltd. An acid addition salt of a nortriptyline-gaba conjugate and a process of preparing same

Also Published As

Publication number Publication date
WO2011104637A2 (en) 2011-09-01
IL221461A0 (en) 2012-10-31
JP2013520488A (ja) 2013-06-06
US20110312948A1 (en) 2011-12-22
EP2539857A2 (en) 2013-01-02
MX2012009821A (es) 2012-10-09
US8377929B2 (en) 2013-02-19
WO2011104637A3 (en) 2012-02-23
AU2011219529A1 (en) 2012-08-30
WO2011104637A9 (en) 2012-01-05
EP2539857A4 (en) 2013-07-24
CN102858345A (zh) 2013-01-02
US20130150352A1 (en) 2013-06-13

Similar Documents

Publication Publication Date Title
US8377929B2 (en) Crystalline forms of the tri-mesylate salt of perphenazine-GABA and process of producing the same
IL189276A (en) Crystalline form ii of a pyridazino [4,5-b] indole derivative
US20220002306A1 (en) Crystal form of upadacitinib and preparation method and use thereof
EP2607370A2 (en) Amorphous form of beta- L-2'-deoxythymidine
JP7702384B2 (ja) Ｖｍａｔ２阻害剤、及びその調製方法、及びその使用
US8916610B2 (en) Acid addition salt of a nortriptyline-GABA conjugate and a process of preparing same
AU2019217821B2 (en) Co-crystal forms of a novobiocin analog and proline
JP2024546844A (ja) ピラゾロ［３，４－ｄ］ピリミジン化合物の固体形態
ES2924432T3 (es) Polimorfos cristalinos de un agonista del receptor de la acetilcolina muscarínica
US9694004B2 (en) Crystal form
CA2741941A1 (en) Choline and tromethamine salt of licofelone
CA2469225C (en) Citric acid salt of 4-(3,4-dichlorophenyl)-2-[2-(4-methylpiperazin-1-yl)-benzylidene]-thiomorpholin-3-one and pharmaceutical compositions thereof
US20130131023A1 (en) New polymorphic form of a calcimimetic compound
EP2042498A1 (en) Crystal of benzoxadiazole derivative
US8569289B2 (en) Fumarate salt of 4-bromophenyl 1,4-diazabicyclo[3.2.2]nonane-4-carboxylate, crystalline forms thereof, preparation thereof and therapeutic use thereof
HK40061049A (en) 2,3,5-TRIMETHYL-6-NONYLCYCLOHEXA-2,5-DIENE-1,4-DIONE FOR SUPPRESSING AND TREATING α-SYNUCLEINOPATHIES, TAUOPATHIES, AND OTHER DISORDERS
HK40068368B (zh) 索吡溴铵的晶型及其制备方法
HK1198534B (en) Novel crystal form
NZ621315B2 (en) Novel crystal form of rilapladib

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20160224